Semaglutide, the next FDA-approved GLP-1RA medication, demonstrates greater weight loss in patients with obesity, mediated by its increased half-life compared to liraglutide through modification to inhibit degradation by dipeptidyl-peptidase-4 (DPP-4) [38]. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.